TOPIC : AMR Accelerator programme Pillar A: Capability Building Network to accelerate and validate scientific discoveries
|Publication date:||18 July 2018|
|Types of action:||IMI2-RIA Research and Innovation action|
|DeadlineModel: Opening date:||two-stage 18 July 2018||Deadline: 2nd stage Deadline:||
24 October 2018 17:00:00
15 May 2019 17:00:00
|Time Zone : (Brussels time)|
Topic DescriptionSpecific Challenge:
There are significant scientific challenges to the discovery and development of new agents to treat and prevent AMR infections, including those caused by Gram-positive and Gram-negative bacteria, Mycobacterium tuberculosis, and non-tubercular mycobacteria (NTM). Models, approaches, and tools to support antibiotic drug development need to be validated and shared more widely to serve the AMR community. Alternative approaches to treating infections and platforms that enhance the success for vaccines and monoclonal antibodies require robust validation. The AMR Accelerator will provide, under one operational structure, a wide-ranging series of projects that will address many of the scientific challenges in AMR.Scope:
The Capability Building Network (CBN), Pillar A of the IMI2 AMR Accelerator programme, will work to address the innovation gap in the AMR space by enabling pre-competitive research in the treatment and prevention of multi-drug resistant infections.
The success of the overall Accelerator relies on a coordinated approach to ensure efficient implementation, management, and strategic alignment across a broad range of topics, partners, and stakeholders. The dual aim of this first call for the CBN will be to:
- create an operational group to support the delivery of projects across the Accelerator, specifically: (1) support the project coordinators in horizontal administration of projects, including project and alliance management; (2) centrally source and implement IT infrastructures for projects in the Accelerator; (3) act as an interface with stakeholders in the AMR field to explore synergies and collaboration with other initiatives and contribute to coordinating the broader AMR strategy on a global scale;
- conduct pre-competitive research aimed to (1) provide learnings derived from shared vaccine and/or antibacterial clinical trial data; (2) improve understanding of variability and translatability of animal models of bacterial infection.
The expected impact of the CBN will be to: (1) contribute to the development of a vibrant AMR research environment in the EU and strengthening the competitiveness and industrial leadership of Europe; (2) contribute to EU’s ambition of being a ‘best practice region’ for addressing AMR; (3) with other elements of the AMR Accelerator, enhance the overall pipeline of medicines for patients with AMR infections; (4) strengthen interaction of AMR stakeholders from across EU and globally; (5) strengthen the scientific basis on AMR research.
Topic conditions and documents
Please read carefully all provisions stated below before the preparation of your application.
The IMI2 JU 15th Call for proposals topics text as well as the Call Conditions are available here.
The budget breakdown for this Call is given at the end of the Call topics text, in the Call Conditions section, as well as the following information :
2. Eligibility and admissibility conditions: described in the IMI2 Manual for evaluation, submission and grant award. See also the Commission Delegated Regulation related to IMI JU.
Proposal page limits and layout: Please refer to Part B of the proposal template in the submission tool below.
Submission and evaluation process, including evaluation criteria and procedure, scoring and threshold are described in the IMI2 Manual for submission, evaluation and grant award. See also the proposal templates for your specific action in section 5, below.
4. Indicative time for evaluation and grant agreement:
Notification of outcomes of stage 1 evaluations: maximum 5 months from deadline for submitting proposals.
Notification of outcomes of stage 2 evaluations: maximum 5 months from deadline for submitting full proposals.
Signature of grant agreements: maximum 3 months from the date of informing successful applicants.
5. Proposal templates, evaluation forms and model grant agreements (MGA):
IMI2 Research and Innovation Action (IMI2-RIA) and Innovation Action (IMI2-IA):
Proposal templates are available after entering the submission tool
Standard evaluation form
Clinical trial template – the Clinical Trial template is compulsory at stage 2 only !
6. Open access must be granted to all scientific publications resulting from Horizon 2020 actions.
Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.
Open access to research data
The Open Research Data Pilot has been extended to cover all Horizon 2020 topics for which the submission is opened on 26 July 2016 or later. Projects funded under this topic will therefore by default provide open access to the research data they generate, except if they decide to opt-out under the conditions described in Annex L of the H2020 main Work Programme. Projects can opt-out at any stage, that is both before and after the grant signature.
Note that the evaluation phase proposals will not be evaluated more favourably because they plan to open or share their data, and will not be penalised for opting out.
Open research data sharing applies to the data needed to validate the results presented in scientific publications. Additionally, projects can choose to make other data available open access and need to describe their approach in a Data Management Plan.
Projects need to create a Data Management Plan (DMP), except if they opt-out of making their research data open access. A first version of the DMP must be provided as an early deliverable within six months of the project and should be updated during the project as appropriate. The Commission already provides guidance documents, including a template for DMPs. See the Online Manual.
Eligibility of costs: costs related to data management and data sharing are eligible for reimbursement during the project duration.
The legal requirements for projects participating in this pilot are in the article 29.3 of the Model Grant Agreement.
Members of consortium are required to conclude a consortium agreement prior to the signature of the grant agreement.
7. Additional documents:
No submission system is open for this topic.
H2020 Online Manual is your guide on the procedures from proposal submission to managing your grant.
Participant Portal FAQ – Submission of proposals.
National Contact Points (NCP) - contact your NCP for further assistance in your national language(s).
Research Enquiry Service – ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.
Enterprise Europe Network – contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.
IT Helpdesk - contact the Participant Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.
European IPR Helpdesk assists you on intellectual property issues
CEN and CENELEC, the European Standards Organisations, advise you how to tackle standardisation in your project proposal. Contact CEN-CENELEC Research Helpdesk at email@example.com
Partner Search Services help you find a partner organisation for your proposal.
IMI2 States Representative Group (SRG) – contact you SRG member for assistance.
IMI2 JU Applicants Helpdesk – contact the IMI2 Programme Office